Michael Antoniou

Mr. Michael Antoniou

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Alexandra SorvinaAlexandra Sorvina
Alexandra Sorvina
MAMichael Antoniou
Michael Antoniou
ZEZahra Esmaeili
Zahra Esmaeili
MKMarina Kochetkova
Marina Kochetkova
The extracellular matrix (ECM) is the complex three-dimensional network of fibrous proteins and proteoglycans that constitutes an essential part of every tissue to provide support for normal tissue homeostasis. Tissue specificity of the ECM in its topology and structure supports unique biochemical and mechanical properties of each organ. Cancers, like normal tissues, require the ECM to maintain multiple processes governing tumor development, progression and spread. A large body of experimental and clinical evidence has now accumulated to demonstrate essential roles of numerous ECM components in all cancer types. Latest findings also suggest that multiple tumor types express, and use to their advantage, atypical ECM components that are not found in the cancer tissue of origin. However, the understanding of cancer-specific expression patterns of these ECM proteins and their exact roles in selected tumor types is still sketchy. In this review, we summarize the latest data on the aberrant expression of bone and cartilage ECM proteins in epithelial cancers and their specific functions in the pathogenesis of carcinomas and discuss future directions in exploring the utility of this selective group of ECM components as future drug targets.

28 June 2026 in Clinical Proteomics
Verified
Journal Article
Open access
JSJack Scanlan
Jack Scanlan
PMParul Mittal
Parul Mittal
JWJennifer Washington
Jennifer Washington
CYClifford Young
Clifford Young
MAMichael Antoniou
Michael Antoniou
MKManuela Klingler-Hoffmann
Manuela Klingler-Hoffmann
Most advanced ovarian cancer patients develop malignant ascites, which describes a buildup of fluid in the peritoneal cavity caused by increased vascular permeability and obstructed lymphatic drainage. Malignant ascites contains cancer cells, which can aggregate as spheroids, as well as stromal cells, cancer-associated fibroblasts, and blood cells that create a complex tumor microenvironment. This study explores the proteome of ascites and how this environment affects the viability, phenotypes, proteomes, and treatment responses of ovarian cancer cells. Using label-free proteomics, we compared the proteomes of cell-free malignant ascites from ovarian cancer patients with those of serum. Additionally, we examined the ex vivo chemotherapy responses of cancer spheroids cultured in ascites. Through detailed proteomic analysis of cells grown as 2D or 3D in tissue culture medium or ascites, we identified biological pathways and specific proteins induced by ascites. Finally, we performed orthogonal validation of a candidate marker, TGM2, using immunofluorescent staining. Proteomics of cell-free ascites identified increased levels of extracellular, secreted, and membrane proteins when compared to serum. Ascites enhanced the baseline cell viability and spheroid formation of immortalized ovarian cancer cell lines compared to standard cell culture medium. However, chemotherapy-induced cell death of spheroids grown in standard cell culture medium remained proportional to changes observed in ascites-cultured spheroids. Ascites-driven phenotypic changes were not recapitulated by adding selected chemokines nor periostin to the cell culture medium, suggesting that additional factors are required. Notably, ascites induced similar ECM, secreted, and membrane proteins across 2D and 3D models, including TGM2, which was validated in spheroids through immunofluorescent staining. This study contributes to our understanding of the role of ascites in the regulation of the proteome and viability of cancer cells. It provides evidence for the induction of TGM2 expression by ascites. Results from this pilot study warrant further study in a larger cohort.